Press Releases Year All202620252024202320222021202020192018201720162015 March 30, 2026 Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network Hope Therapeutics (subsidiary of NRx Pharmaceuticals, Nasdaq: NRXP) partners with Emobot Health to deploy its AI-powered "Depression Thermometer" across its interventional psychiatry clinic network. Emobot's platform passively monitors depression, bipolar disorder and anxiety disorders via Read More March 24, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress Key highlights for the first full year of operation under the new management team include: A year-over-year reduction in operating expenses with $7.8 Million cash on hand at year end. With ongoing revenue from operations and current ATM trends, the Company anticipates adequate resources to support Read More March 19, 2026 NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026 WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026. Read More March 17, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx’s Preservative-Free Ketamine Application Determination of bioequivalence to the Reference Listed Drug is essential for approval of an Abbreviated New Drug Application (ANDA). FDA has advised NRx in written correspondence that it has not identified any bioequivalence deficiencies in the Company’s Preservative-Free Ketamine product. Read More March 16, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting NRx has received confirmatory FDA minutes from in-person Type C meeting attended by leadership of FDA Division of Psychiatry, FDA Office of Neuroscience, and FDA Center for Drug Evaluation and Research. Minutes are consistent with previously announced oral guidance outlining a path to New Drug Read More March 9, 2026 HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD Published results have shown 87% clinical response to non-invasive Transcranial Magnetic Stimulation with neuroplastic medications. Clinical leadership by physicians trained at Harvard, Johns Hopkins, Georgetown, and other leading Universities. Now accepting patients, call 1-833-4HOPETMS WEST PALM Read More March 2, 2026 NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal. Extensive publication history in the science of neuroplasticity and its relationship to healing Read More February 17, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting NRx together with Osmind, Inc. conducted an in-person meeting attended by leadership of the FDA Division of Psychiatry Products and leadership of the FDA Center for Drug Evaluation and Research (CDER) Oral guidance received at the meeting provides a path to filing an application for New Drug Read More January 16, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date WILMINGTON, Del., Jan. 16, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) (the “Company”), a clinical-stage biopharmaceutical company, today announced that it will hold its annual meeting of stockholders (the “2025 Annual Meeting”) on March 23, 2026 at 10:00 a.m. Read More January 14, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval NRX-100 (preservative-free ketamine) has been granted Fast Track Designation by FDA for treatment of suicidal ideation in patients with Depression and Bipolar Depression. Real-world evidence, consistent with FDA guidance, is supplied and generated by Osmind using its nationwide electronic medical Read More Corporate Presentation Click here to view our corporate presentation or on the image below IP Portfolio View Our Pipeline Contact NRx Pharmaceuticals
Year All202620252024202320222021202020192018201720162015 March 30, 2026 Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network Hope Therapeutics (subsidiary of NRx Pharmaceuticals, Nasdaq: NRXP) partners with Emobot Health to deploy its AI-powered "Depression Thermometer" across its interventional psychiatry clinic network. Emobot's platform passively monitors depression, bipolar disorder and anxiety disorders via Read More March 24, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress Key highlights for the first full year of operation under the new management team include: A year-over-year reduction in operating expenses with $7.8 Million cash on hand at year end. With ongoing revenue from operations and current ATM trends, the Company anticipates adequate resources to support Read More March 19, 2026 NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026 WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026. Read More March 17, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx’s Preservative-Free Ketamine Application Determination of bioequivalence to the Reference Listed Drug is essential for approval of an Abbreviated New Drug Application (ANDA). FDA has advised NRx in written correspondence that it has not identified any bioequivalence deficiencies in the Company’s Preservative-Free Ketamine product. Read More March 16, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting NRx has received confirmatory FDA minutes from in-person Type C meeting attended by leadership of FDA Division of Psychiatry, FDA Office of Neuroscience, and FDA Center for Drug Evaluation and Research. Minutes are consistent with previously announced oral guidance outlining a path to New Drug Read More March 9, 2026 HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD Published results have shown 87% clinical response to non-invasive Transcranial Magnetic Stimulation with neuroplastic medications. Clinical leadership by physicians trained at Harvard, Johns Hopkins, Georgetown, and other leading Universities. Now accepting patients, call 1-833-4HOPETMS WEST PALM Read More March 2, 2026 NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal. Extensive publication history in the science of neuroplasticity and its relationship to healing Read More February 17, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting NRx together with Osmind, Inc. conducted an in-person meeting attended by leadership of the FDA Division of Psychiatry Products and leadership of the FDA Center for Drug Evaluation and Research (CDER) Oral guidance received at the meeting provides a path to filing an application for New Drug Read More January 16, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date WILMINGTON, Del., Jan. 16, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) (the “Company”), a clinical-stage biopharmaceutical company, today announced that it will hold its annual meeting of stockholders (the “2025 Annual Meeting”) on March 23, 2026 at 10:00 a.m. Read More January 14, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval NRX-100 (preservative-free ketamine) has been granted Fast Track Designation by FDA for treatment of suicidal ideation in patients with Depression and Bipolar Depression. Real-world evidence, consistent with FDA guidance, is supplied and generated by Osmind using its nationwide electronic medical Read More
March 30, 2026 Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network Hope Therapeutics (subsidiary of NRx Pharmaceuticals, Nasdaq: NRXP) partners with Emobot Health to deploy its AI-powered "Depression Thermometer" across its interventional psychiatry clinic network. Emobot's platform passively monitors depression, bipolar disorder and anxiety disorders via Read More
March 24, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress Key highlights for the first full year of operation under the new management team include: A year-over-year reduction in operating expenses with $7.8 Million cash on hand at year end. With ongoing revenue from operations and current ATM trends, the Company anticipates adequate resources to support Read More
March 19, 2026 NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026 WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026. Read More
March 17, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx’s Preservative-Free Ketamine Application Determination of bioequivalence to the Reference Listed Drug is essential for approval of an Abbreviated New Drug Application (ANDA). FDA has advised NRx in written correspondence that it has not identified any bioequivalence deficiencies in the Company’s Preservative-Free Ketamine product. Read More
March 16, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting NRx has received confirmatory FDA minutes from in-person Type C meeting attended by leadership of FDA Division of Psychiatry, FDA Office of Neuroscience, and FDA Center for Drug Evaluation and Research. Minutes are consistent with previously announced oral guidance outlining a path to New Drug Read More
March 9, 2026 HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD Published results have shown 87% clinical response to non-invasive Transcranial Magnetic Stimulation with neuroplastic medications. Clinical leadership by physicians trained at Harvard, Johns Hopkins, Georgetown, and other leading Universities. Now accepting patients, call 1-833-4HOPETMS WEST PALM Read More
March 2, 2026 NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal. Extensive publication history in the science of neuroplasticity and its relationship to healing Read More
February 17, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting NRx together with Osmind, Inc. conducted an in-person meeting attended by leadership of the FDA Division of Psychiatry Products and leadership of the FDA Center for Drug Evaluation and Research (CDER) Oral guidance received at the meeting provides a path to filing an application for New Drug Read More
January 16, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date WILMINGTON, Del., Jan. 16, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) (the “Company”), a clinical-stage biopharmaceutical company, today announced that it will hold its annual meeting of stockholders (the “2025 Annual Meeting”) on March 23, 2026 at 10:00 a.m. Read More
January 14, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval NRX-100 (preservative-free ketamine) has been granted Fast Track Designation by FDA for treatment of suicidal ideation in patients with Depression and Bipolar Depression. Real-world evidence, consistent with FDA guidance, is supplied and generated by Osmind using its nationwide electronic medical Read More
